0000899243-19-023936.txt : 20190919
0000899243-19-023936.hdr.sgml : 20190919
20190919190535
ACCESSION NUMBER: 0000899243-19-023936
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190917
FILED AS OF DATE: 20190919
DATE AS OF CHANGE: 20190919
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Koppel Adam
CENTRAL INDEX KEY: 0001578965
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39044
FILM NUMBER: 191102458
MAIL ADDRESS:
STREET 1: C/O BROOKSIDE CAPITAL, LLC
STREET 2: JOHN HANCOCK TOWER, 200 CLARENDON ST
CITY: BOSTON
STATE: MA
ZIP: 02116
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Schwartz Jeffrey Lawrence
CENTRAL INDEX KEY: 0001702957
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39044
FILM NUMBER: 191102459
MAIL ADDRESS:
STREET 1: C/O BAIN CAPITAL LIFE SCIENCES, LP
STREET 2: 200 CLARENDON STRERET
CITY: BOSTON
STATE: MA
ZIP: 02116
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: BC SW, LP
CENTRAL INDEX KEY: 0001786351
STATE OF INCORPORATION: MA
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39044
FILM NUMBER: 191102460
BUSINESS ADDRESS:
STREET 1: 200 CLAREDON STREET
CITY: BOSTON
STATE: MA
ZIP: 02116
BUSINESS PHONE: 6175162000
MAIL ADDRESS:
STREET 1: 200 CLARENDON STREET
CITY: BOSTON
STATE: MA
ZIP: 02116
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Bain Capital Life Sciences Investors, LLC
CENTRAL INDEX KEY: 0001703031
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39044
FILM NUMBER: 191102461
BUSINESS ADDRESS:
STREET 1: 200 CLARENDON STREET
CITY: BOSTON
STATE: MA
ZIP: 02116
BUSINESS PHONE: 6175162878
MAIL ADDRESS:
STREET 1: 200 CLARENDON STREET
CITY: BOSTON
STATE: MA
ZIP: 02116
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: SpringWorks Therapeutics, Inc.
CENTRAL INDEX KEY: 0001773427
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 100 WASHINGTON BOULEVARD
CITY: STAMFORD
STATE: CT
ZIP: 06902
BUSINESS PHONE: 203-883-9490
MAIL ADDRESS:
STREET 1: 100 WASHINGTON BOULEVARD
CITY: STAMFORD
STATE: CT
ZIP: 06902
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2019-09-17
0
0001773427
SpringWorks Therapeutics, Inc.
SWTX
0001703031
Bain Capital Life Sciences Investors, LLC
200 CLARENDON STREET
BOSTON
MA
02116
0
0
1
0
0001786351
BC SW, LP
200 CLARENDON STREET
BOSTON
MA
02116
0
0
1
0
0001702957
Schwartz Jeffrey Lawrence
C/O BAIN CAPITAL LIFE SCIENCES INVESTORS
LLC, 200 CLARENDON STREET
BOSTON
MA
02116
1
0
1
0
0001578965
Koppel Adam
200 CLARENDON STREET
BOSTON
MA
02116
0
0
1
0
Common Stock
2019-09-17
4
C
0
6078103
A
6078103
I
See Footnotes
Common Stock
2019-09-17
4
C
0
1053204
A
7131307
I
See Footnotes
Common Stock
2019-09-17
4
P
0
150000
18.00
A
7281307
I
See Footnotes
Series A Convertible Preferred Stock
2019-09-17
4
C
0
6078103
D
Common Stock
6078103
0
I
See Footnotes
Series B Convertible Preferred Stock
2019-09-17
4
C
0
1053204
D
Common Stock
1053204
0
I
See Footnotes
Each share of Series A Convertible Preferred Stock was convertible into shares of the Issuer's Common Stock on a 6.5810:1 basis. Upon the closing of the Issuer's initial public offering, all shares of Series A Convertible Preferred Stock automatically converted into shares of Common Stock of the Issuer. The Series A Convertible Preferred Stock had no expiration date.
Each share of Series B Convertible Preferred Stock was convertible into shares of the Issuer's Common Stock on a 6.5810:1 basis. Upon the closing of the Issuer's initial public offering, all shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock of the Issuer. The Series B Convertible Preferred Stock had no expiration date.
Represents shares purchased in the Issuer's initial public offering.
Represents shares held directly by BC SW, L.P.
Bain Capital Life Sciences Investors, LLC ("BCI LS"), whose managers are Jeffrey Schwartz and Adam Koppel, is the general partner of BC SW, L.P. As a result, each of BCI LS, Mr. Schwartz and Dr. Koppel may be deemed to share voting and dispositive power with respect to the securities held by BC SW, L.P. BCI LS, Mr. Schwartz and Dr. Koppel each disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein.
Jeffrey Schwartz is a director of the Issuer.
Bain Capital Life Sciences Investors, LLC, By: /s/ Jeffery L. Schwartz, Name: Jeffery L. Schwartz, Title: Managing Director
2019-09-19
BC SW, L.P., By: Bain Capital Life Sciences Investors, LLC, its general partner, By: /s/ Jeffery L. Schwartz, Name: Jeffery L. Schwartz, Title: Managing Director
2019-09-19
/s/Jeffery L. Schwartz
2019-09-19
/s/ Adam Koppel
2019-09-19